2016
Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle
Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle. Journal Of Endourology 2016, 30: 709-713. PMID: 27072291, DOI: 10.1089/end.2016.0046.Peer-Reviewed Original ResearchMeSH KeywordsCarboxymethylcellulose SodiumErectile DysfunctionHumansHyaluronic AcidKaplan-Meier EstimateLaparoscopyMaleMiddle AgedNeoplasm Recurrence, LocalPenile ErectionPostoperative PeriodProspective StudiesProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeConceptsErectile functionNeurovascular bundleBiochemical recurrenceGood baseline erectile functionPreoperative prostate-specific antigenRobot-assisted laparoscopic prostatectomyBaseline erectile functionPreoperative SHIM scoreSexual Health InventoryAUA symptom scorePostoperative erectile functionKaplan-Meier analysisNerve-sparing prostatectomyProstate-specific antigenSignificant differencesMean SHIMSHIM scoreIndependent t-testMedian followOncologic outcomesConsecutive patientsOperative timeRetrospective reviewProstate sizeSymptom scores
2015
Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusNeutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification tool
2014
Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH
Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals Of Surgical Oncology 2014, 22: 2439-2445. PMID: 25348783, DOI: 10.1245/s10434-014-4194-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorCalgranulin ACalgranulin BCase-Control StudiesFollow-Up StudiesHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNucleic AcidsPrognosisProstatic HyperplasiaProstatic NeoplasmsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsS100A8/A9CAP patientsAcid levelsNucleic acid levelBPH tissueProstate cancerS100A8/A9 expressionBenign prostatic hyperplasia tissuesRecurrence-free timeProstatic hyperplasia tissuesUrinary nucleic acidsBPH patientsIndependent predictorsTransurethral resectionAggressive diseaseChronic inflammationPoor prognosisPrognostic valueTransurethral prostatectomyProstatectomy patientsBiochemical recurrencePrognostic markerS100A9 expressionA9 expressionImmunohistochemical stainingCytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchMeSH KeywordsCytoreduction Surgical ProceduresHumansMaleNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingProstate-Specific AntigenProstatectomyProstatic NeoplasmsSurvival AnalysisConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapyThe predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer
Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2014, 32: 458-465. PMID: 24411789, DOI: 10.1016/j.urolonc.2013.10.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBCG VaccineCarcinoma, Transitional CellFemaleFollow-Up StudiesGenotypeGlutathione TransferaseHumansMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPolymorphism, GeneticPrognosisRisk FactorsSmokingSurvival RateUrinary Bladder NeoplasmsConceptsNon-muscle invasive bladder cancerGSTT1-positive genotypeInvasive bladder cancerPrimary non-muscle invasive bladder cancerBCG failureBladder cancerPredictive valueInduction therapyIndependent predictorsHigh riskBacillus Calmette-Guérin induction therapyNull genotypeMultivariate logistic regression analysisMultivariate logistic regression modelBCG induction therapyInduction BCG therapySingle induction courseDisease-free survivalGlutathione S-transferase muKaplan-Meier analysisHigh-risk groupKaplan-Meier estimatesEarly responseLogistic regression analysisGSTT1 null genotype
2012
Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellChildDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPromoter Regions, GeneticProportional Hazards ModelsTumor BurdenTumor Suppressor ProteinsUrinary Bladder NeoplasmsYoung AdultConceptsRecurrent nonmuscle invasive bladder cancerNonmuscle invasive bladder cancerMuscle-invasive bladder cancerInvasive bladder cancerPrimary BC tissuesCox regression analysisBladder cancerPrognostic markerRASSF1A methylationRASSF1A hypermethylationIndependent predictorsBC tissuesMultivariate Cox regression analysisCancer progressionKaplan-Meier analysisAdvanced tumor stagePromising prognostic markerPromoter hypermethylationPotential prognostic markerRegression analysisRASSF1A promoter hypermethylationMethylation-specific polymerase chain reactionClinicopathologic featuresPrognostic significanceKaplan-Meier
2011
RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumorsPathologic implications of prostatic anterior fat pad
Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad. Urologic Oncology Seminars And Original Investigations 2011, 31: 63-67. PMID: 21396837, DOI: 10.1016/j.urolonc.2010.09.003.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padRobot-assisted radical prostatectomyMetastatic prostate cancerLymph nodesProstate cancerAnterior fat padPSA levelsRadical prostatectomyLymphoid tissuePathologic analysisFat padPathologic implicationsSignificant pathologic differencesHigh-risk featuresPelvic lymph nodesRetrospective chart reviewLymph node statusProstate cancer patientsChart reviewConsecutive patientsPathologic stagingRoutine excisionNode statusBiochemical recurrenceCancer patients
2010
Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method
Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method. Annals Of Surgical Oncology 2010, 18: 1775-1781. PMID: 21184188, DOI: 10.1245/s10434-010-1500-7.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerBladder cancerPolymerase chain reactionNonmuscle invasive bladder cancer patientsHOGG1 codon 326 genotypesProgression-free survival benefitInvasive bladder cancer patientsTumor tissueTissue genotypeHOGG1 codon 326Primary BC patientsCox regression analysisInvasive bladder cancerBladder cancer prognosisPrimary bladder cancerAggressive clinicopathological featuresBladder cancer patientsReal-time polymerase chain reactionSurvival benefitBC prognosisClinicopathological characteristicsClinicopathological featuresBC patientsPrognostic indicatorCancer patientsHMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression
Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression. Journal Of Urology 2010, 185: 701-705. PMID: 21168882, DOI: 10.1016/j.juro.2010.09.081.Peer-Reviewed Original ResearchAgedBiomarkers, TumorBiopsy, NeedleCarcinoma, Transitional CellCohort StudiesCystectomyDisease ProgressionFemaleGene Expression Regulation, NeoplasticHeme Oxygenase-1HumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSensitivity and SpecificitySurvival AnalysisUrinary Bladder Neoplasms
2001
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsMuscle-invasive transitional cell carcinomaTransitional cell carcinomaT1 transitional cell carcinomaPreoperative plasma levelsPlasma TGFDisease recurrenceIndependent predictorsLymph nodesClinical outcomesPlasma levelsBladder carcinomaGrowth factorDisease-specific mortalityDisease-specific survivalRegional lymph nodesSubgroup of patientsStrong independent predictorGrowth factor-β1Intravesical immunoCarcinoma metastaticLymphovascular invasionSpecific survivalRadical cystectomyPathologic featuresCell carcinomaPreoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status